Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Onureg (azacitidine oral)
i
Other names:
CC 486, CC-486, BMS-986345, BMS986345, CC486, BMS 986345
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Trials
Company:
BMS
Drug class:
DNMT inhibitor
Related drugs:
‹
azacitidine (75)
decitabine (40)
decitabine/cedazuridine (10)
NTX-301 (1)
OR-2100 (0)
ASTX030 (0)
SGI-110 (0)
azacitidine (75)
decitabine (40)
decitabine/cedazuridine (10)
NTX-301 (1)
OR-2100 (0)
ASTX030 (0)
SGI-110 (0)
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
MYC overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
DNMT3A mutation
Peripheral T-cell Lymphoma
DNMT3A mutation
Peripheral T-cell Lymphoma
azacitidine oral
Resistant: C3 – Early Trials
azacitidine oral
Resistant
:
C3
azacitidine oral
Resistant: C3 – Early Trials
azacitidine oral
Resistant
:
C3
TET2 mutation
Peripheral T-cell Lymphoma
TET2 mutation
Peripheral T-cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
ITGAM expression
Acute Myelogenous Leukemia
ITGAM expression
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: D – Preclinical
azacitidine oral
Sensitive
:
D
azacitidine oral
Sensitive: D – Preclinical
azacitidine oral
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login